Creating An Efficient Clinical Trial Build System via The Clinical Trials Rapid Activation Consortium (CTRAC)
Creating An Efficient Clinical Trial Build System via The Clinical Trials Rapid Activation Consortium (CTRAC)
批准号:
10227524
负责人:
HOWARD H. BAILEY
金额:
$30.02万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-01 至 2023-03-31
关键词:
AddressAdverse eventAreaAutomationCancer BurdenCancer CenterCatchment AreaClinicalClinical TrialsClinical Trials NetworkClinical trial protocol documentCommunitiesComplexCustomDevelopmentDiseaseEducationElectronic Health RecordExpenditureFormulariesFutureGoalsIndividualInfrastructureInstitutionIntervention StudiesInvestigational TherapiesLaboratoriesLeadershipMalignant NeoplasmsManualsMedication ErrorsMentorshipMethodsMissionModificationPatient CarePatientsPharmaceutical PreparationsPoliciesPopulation ResearchProceduresProcessProtocols documentationProviderResearchResearch PersonnelResourcesSiteSpecific qualifier valueStandardizationStructureSystemTestingTimeUniversitiesVendorWisconsinWorkanticancer researcharmbasecancer carecare providerscostimaging biomarkerimprovedinnovationmemberneoplasm resourcenext generationnovelpopulation basedstandard of caresupport networktreatment planning
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Standard-of-care electronic health records (EHR)-based treatment plans support efficiency and quality
through standardization. However, treatment-plan builds for clinical trials, irrespective of the number of
patients, must be built from the ground up for each new trial and at each added site. Additionally,
investigational treatment plans often require configurations for novel medications, numerous ancillary
procedures, and research finance requirements. The current paradigm is costly, complex, and
inefficient. Representatives of five cancer centers agreed to be part of the project’s Clinical Trials Rapid
Activation Consortium (CTRAC). The project’s goal is to develop processes across multiple NCI-supported
cancer centers that will facilitate the development of single builds of EHR clinical-trial treatment plans that
can be deployed at multiple institutions in support of NCI- sponsored network studies. Members will
investigate the question: can a small consortium of clinical trials sites develop methods to standardize
workflows, drug formularies, drug administration procedures, and laboratory requirements leading to the
creation of the components for a standardized, electronic, clinical trials build system? Specific aims are as
follows: 1) To identify the tasks currently performed by EHR investigational treatment plans (SOPs, policies,
and workflows) and to define differences among these SOPs at the individual member sites of the
consortium; 2) To standardize the processes within each task where possible and document differences that
would require modifications across sites; 3) To develop a master assessment of EHR treatment-plan
modules that could be reused to perform components of the same research protocol tasks at multiple sites
while maintaining compliance with the requirements of member organizations of the consortium; 4) To
organize a leadership structure for the consortium that will work with the NCI and an EHR provider to
oversee this initiative to assure that adequate progress is made toward the ultimate goal of creating a more
automated electronic clinical-trial build system that will facilitate the activation of clinical trials across all NCI-
supported networks; 5) To build standardized electronic clinical-trial build modules that could undergo future
pilot testing at each institution for a specified group of NCI-sponsored clinical trials; and 6) To facilitate
development of metrics for the new EHR processes that can demonstrate whether more consistent patient
care, reduced medication errors, and fewer adverse events result from a standardized approach to clinical-
trial build modules.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Stress keratin 17 and CD4/8 ratio as prognostic markers in HIV-related anogenital squamous cell precancers and cancers (Biospecimens/Biocohort)
-
批准号:10620051
-
项目类别:
-
资助金额:$23.9万
-
财政年份:2022
-
负责人:HOWARD H. BAILEY
-
依托单位:
Defining Tumor Microenvironment and Response to Immune Checkpoint Blockade in HIV-related Anogenital Squamous Cell Carcinomas (Immuno/microenvironment)
-
批准号:10620043
-
项目类别:
-
资助金额:$24.47万
-
财政年份:2022
-
负责人:HOWARD H. BAILEY
-
依托单位:
The MW Cancer Prevention Clinical Trials Network
-
批准号:10252839
-
项目类别:
-
资助金额:$171.64万
-
财政年份:2020
-
负责人:HOWARD H. BAILEY
-
依托单位:
The MW Cancer Prevention Clinical Trials Network
-
批准号:10475114
-
项目类别:
-
资助金额:$165.26万
-
财政年份:2020
-
负责人:HOWARD H. BAILEY
-
依托单位:
The MW Cancer Prevention Clinical Trials Network
-
批准号:10004825
-
项目类别:
-
资助金额:$84.54万
-
财政年份:2020
-
负责人:HOWARD H. BAILEY
-
依托单位:
Protocol Specific
-
批准号:8250423
-
项目类别:
-
资助金额:$11.7万
-
财政年份:2011
-
负责人:HOWARD H. BAILEY
-
依托单位:
Clinical Research Central Office
-
批准号:8250421
-
项目类别:
-
资助金额:$32.25万
-
财政年份:2011
-
负责人:HOWARD H. BAILEY
-
依托单位:
Program Leaders
-
批准号:8250405
-
项目类别:
-
资助金额:$23.3万
-
财政年份:2011
-
负责人:HOWARD H. BAILEY
-
依托单位:
Program Leaders
-
批准号:7491879
-
项目类别:
-
资助金额:$22.73万
-
财政年份:2007
-
负责人:HOWARD H. BAILEY
-
依托单位:
Clinical Research Central Office
-
批准号:7491898
-
项目类别:
-
资助金额:$29.63万
-
财政年份:2007
-
负责人:HOWARD H. BAILEY
-
依托单位:
Protocol Specific
-
批准号:7491902
-
项目类别:
-
资助金额:$13.82万
-
财政年份:2007
-
负责人:HOWARD H. BAILEY
-
依托单位:
PHASE 2B DFMO CHEMOPREVENTION OF SKIN CANCERS IN ORGAN TRANSPLANT RECIPIENTS
-
批准号:7607508
-
项目类别:
-
资助金额:$0.36万
-
财政年份:2006
-
负责人:HOWARD H. BAILEY
-
依托单位:
PHASE 2B DFMO CHEMOPREVENTION OF SKIN CANCERS IN ORGAN TRANSPLANT RECIPIENTS
-
批准号:7375510
-
项目类别:
-
资助金额:$2.11万
-
财政年份:2005
-
负责人:HOWARD H. BAILEY
-
依托单位:
CHEMOPREVENTION OF SKIN CANCER: DIFLUOROMETHYLORNITHINE (DFMO) PHASE III TRIAL
-
批准号:7204405
-
项目类别:
-
资助金额:$3.86万
-
财政年份:2005
-
负责人:HOWARD H. BAILEY
-
依托单位:
PHASE 2B DFMO CHEMOPREVENTION OF SKIN CANCERS IN ORGAN TRANSPLANT RECIPIENTS
-
批准号:7204368
-
项目类别:
-
资助金额:$0.64万
-
财政年份:2005
-
负责人:HOWARD H. BAILEY
-
依托单位:
Chemoprevention of Skin Cancer: Difluoromethylornithine (DFMO) Phase III Trial
-
批准号:7043935
-
项目类别:
-
资助金额:$4.39万
-
财政年份:2003
-
负责人:HOWARD H. BAILEY
-
依托单位:
Phase 1 and Phase 2 Clinical Trials of Cancer Chemoprevention Agents
-
批准号:8339910
-
项目类别:
-
资助金额:$158.66万
-
财政年份:2003
-
负责人:HOWARD H. BAILEY
-
依托单位:
Phase 1 and Phase 2 Clinical Trials of Cancer Chemoprevention Agents
-
批准号:7943303
-
项目类别:
-
资助金额:$166.4万
-
财政年份:2003
-
负责人:HOWARD H. BAILEY
-
依托单位:
DFMO Prevention Study (2b) in Organ Transplant Subjects
-
批准号:6794941
-
项目类别:
-
资助金额:$25.03万
-
财政年份:2002
-
负责人:HOWARD H. BAILEY
-
依托单位:
DFMO Prevention Study (2b) in Organ Transplant Subjects
-
批准号:6542001
-
项目类别:
-
资助金额:$25.09万
-
财政年份:2002
-
负责人:HOWARD H. BAILEY
-
依托单位:
海外基金